Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
Agios Pharmaceuticals (NASDAQ: AGIO), a company focused on cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 14, 2025, at 8:00 AM PT/11:00 AM ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A recording of the presentation will remain available on the company's website for a minimum of two weeks after the event.
Agios Pharmaceuticals (NASDAQ: AGIO), un'azienda specializzata in terapie basate sul metabolismo cellulare e l'attivazione di PK per malattie rare, ha annunciato la sua prossima partecipazione alla BofA Securities 2025 Health Care Conference. La presentazione è programmata per il 14 maggio 2025, alle 8:00 AM PT/11:00 AM ET. Investitori e interessati potranno seguire la diretta streaming tramite la sezione Investors del sito web di Agios, nella pagina "Events & Presentations". Una registrazione della presentazione sarà disponibile sul sito aziendale per almeno due settimane dopo l'evento.
Agios Pharmaceuticals (NASDAQ: AGIO), una empresa centrada en terapias de activación de metabolismo celular y PK para enfermedades raras, ha anunciado su próxima participación en la BofA Securities 2025 Health Care Conference. La presentación está programada para el 14 de mayo de 2025, a las 8:00 AM PT/11:00 AM ET. Inversores y partes interesadas podrán acceder a la transmisión en vivo a través de la sección de Investors en el sitio web de Agios, bajo "Events & Presentations". La grabación de la presentación estará disponible en el sitio web de la compañía durante al menos dos semanas después del evento.
Agios Pharmaceuticals (NASDAQ: AGIO)는 희귀 질환을 위한 세포 대사 및 PK 활성화 치료법에 중점을 둔 기업으로, BofA Securities 2025 Health Care Conference에 참여할 예정임을 발표했습니다. 발표는 2025년 5월 14일 오전 8시 PT/오전 11시 ET에 예정되어 있습니다. 투자자 및 관심 있는 분들은 Agios 웹사이트의 Investors 섹션 내 "Events & Presentations"에서 라이브 웹캐스트를 시청할 수 있습니다. 발표 녹화본은 행사 후 최소 2주간 회사 웹사이트에서 제공됩니다.
Agios Pharmaceuticals (NASDAQ : AGIO), une entreprise spécialisée dans les thérapies d'activation du métabolisme cellulaire et de la PK pour les maladies rares, a annoncé sa prochaine participation à la BofA Securities 2025 Health Care Conference. La présentation est prévue pour le 14 mai 2025 à 8h00 PT / 11h00 ET. Les investisseurs et les parties intéressées pourront accéder à la diffusion en direct via la section Investors du site web d'Agios, sous "Events & Presentations". Un enregistrement de la présentation restera disponible sur le site de l'entreprise pendant au moins deux semaines après l'événement.
Agios Pharmaceuticals (NASDAQ: AGIO), ein Unternehmen, das sich auf Zellstoffwechsel- und PK-Aktivierungstherapien für seltene Krankheiten spezialisiert hat, hat seine bevorstehende Teilnahme an der BofA Securities 2025 Health Care Conference angekündigt. Die Präsentation ist für den 14. Mai 2025, 8:00 Uhr PT/11:00 Uhr ET geplant. Investoren und Interessierte können den Live-Webcast über den Bereich Investors auf der Webseite von Agios unter "Events & Presentations" verfolgen. Eine Aufzeichnung der Präsentation wird mindestens zwei Wochen nach der Veranstaltung auf der Unternehmenswebseite verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET.
The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When is Agios Pharmaceuticals (AGIO) presenting at the BofA Securities Healthcare Conference 2025?
How can investors access Agios Pharmaceuticals' (AGIO) BofA Securities conference presentation?
How long will Agios Pharmaceuticals' (AGIO) BofA Securities conference presentation be available for replay?
What is Agios Pharmaceuticals' (AGIO) main business focus?
